Mitsubishi Tanabe Pharma Corporation said on October 1 that it has obtain exclusive rights to develop and commercialize Regeneron Pharmaceuticals Inc.’s NGF antibody fasinumab in Japan, Korea, and other Asian regions excluding China. Under a collaboration pact inked on September…
To read the full story
Related Article
- Mitsubishi Tanabe Begins Japan PII/III for Regeneron Pain Med
August 18, 2017
BUSINESS
- JCR’s Izcargo Reels in Conditional Approval in Kuwait
October 15, 2026
- Nxera Licenses Quviviq to Taiwan’s Synmosa in 8 APAC Markets
October 15, 2026
- Rhythm’s Imcivree Debuts in Japan for Acquired Hypothalamic Obesity
October 15, 2026
- Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
- Asahi Kasei’s Pritelivir Scores US Approval for HSV Infections
October 14, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





